ERYTECH reports additional positive Phase III results from clinical study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia

  • Post author:
  • Post category:Newsroom

ERYTECH reports additional positive Phase III results from the pivotal study with eryaspase/GRASPA® in Acute Lymphoblastic Leukemia.

Menu